Montpellier Cedex 5

• Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending
  2025-523400-72-00 4 Cystic fibrosis
• A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participant … Pending
  2025-523481-24-00 5 Participants with Progressive Supranuclear Palsy Richardson Syndrome (
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression
• An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Pending
  2025-523579-47-00 4 moderate to severe rheumatoid arthritis (RA)
• A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Pending
  2025-523911-13-00 5 Narcolepsy Type 1
• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending
  2025-524078-40-00 5 Chronic Spontaneous Urticaria
• Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial Pending
  2025-524297-42-00 5 CLTI defined as Rutherford category 4 or 5
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending
  2025-524316-11-00 5 Primary Progressive Multiple Sclerosis (PPMS)
• Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes Pending
  2025-524395-30-00 6 heart failure
• Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m … Pending
  2025-524408-30-01 5 Metastatic hormone-sensitive prostate cancer
• Staging of gastric cancers by PET-FAPI Pending
  2025-524434-25-00 4 gastric cancer
• OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Pending
  2025-524573-16-00 6 Crohn's disease
• Intravenous iron in the management of drug-resistant restless legs syndrome Pending
  2026-525613-31-00 4 Restless legs syndrome
• Postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stent FRENCH24 ANIS Recruiting
  2024-515181-14-00 5 2026-05-20 Patients with preoperative biliary stent treated by pancreaticoduodene
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo … Recruiting
  2025-522093-36-00 10 2026-05-20 Cancer cachexia
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre … Recruiting
  2025-524366-21-00 5 2026-04-29 treatment-naive Chronic Lymphocytic Leukemia
• Safety, tolerability, pharmacokinetics, and efficacy of filgotinib for the treatment of polyarticular-course juvenile idiopathic arthritis i … Recruiting
  2024-511593-70-00 5 2026-04-27 Polyarticular-course juvenile idiopathic arthritis
• A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Recruiting
  2025-522867-13-00 4 2026-04-27 Non Small Cell Lung Cancer
• A study to test the safety and disease progression following YTB323 (rapcabtagene autoleucel) administration in participant with progressive … Recruiting
  2024-514006-31-00 9 2026-04-16 Non-active Progressive Multiple Sclerosis (PMS)
• Prospective pilot study of L-dopa treatment in patients with a neurodevelopmental disorder linked to a pathogenic variant of the CTNNB1 gene Recruiting
  2024-514852-34-01 4 2026-04-08 Neurodevelopmental disorders
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced

Showing 73–96 of 830 trials